Swiss pharmaceutical group Roche agrees to acquire US-based PathAI, which makes AI diagnostic tools, for up to $1.05B, with $750M upfront, closing in H2 2026 (Adrià Calatayud/Wall Street Journal)

Adrià Calatayud / Wall Street Journal: Swiss pharmaceutical group Roche agrees to acquire US-based PathAI, which makes AI diagnostic tools, for up to $1.05B, with $750M upfront, closing in H2 2026 - The pharma giant has agreed to pay $750M upfront, with up to $300M in additional payments subject to targets